Meanwhile, bortezomib (BTZ), a proteasome inhibitor that has been approved by FDA for the clinical treatment of multiple myeloma (MM),28 was used to restore ATF4 expression in chemoresistant cells. Here, ATF4 is linked to Miyoshi myopathy.